TG Therapeutics, Inc. (NASDAQ:TGTX) Shares Sold by Quantum Private Wealth LLC

Quantum Private Wealth LLC cut its holdings in shares of TG Therapeutics, Inc. (NASDAQ:TGTX) by 1.0% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 102,804 shares of the biopharmaceutical company’s stock after selling 1,000 shares during the quarter. TG Therapeutics accounts for 1.0% of Quantum Private Wealth LLC’s investment portfolio, making the stock its 17th largest position. Quantum Private Wealth LLC’s holdings in TG Therapeutics were worth $3,094,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in TGTX. Valeo Financial Advisors LLC raised its stake in shares of TG Therapeutics by 32.4% in the fourth quarter. Valeo Financial Advisors LLC now owns 13,532 shares of the biopharmaceutical company’s stock valued at $407,000 after acquiring an additional 3,309 shares in the last quarter. Blue Trust Inc. raised its position in TG Therapeutics by 24.5% in the 4th quarter. Blue Trust Inc. now owns 1,887 shares of the biopharmaceutical company’s stock valued at $57,000 after purchasing an additional 371 shares in the last quarter. New York State Teachers Retirement System boosted its stake in shares of TG Therapeutics by 1.9% in the 4th quarter. New York State Teachers Retirement System now owns 43,764 shares of the biopharmaceutical company’s stock valued at $1,317,000 after buying an additional 837 shares during the period. Castellan Group acquired a new position in shares of TG Therapeutics during the fourth quarter worth about $8,539,000. Finally, Van ECK Associates Corp purchased a new stake in shares of TG Therapeutics during the fourth quarter worth approximately $4,219,000. Hedge funds and other institutional investors own 58.58% of the company’s stock.

Wall Street Analysts Forecast Growth

TGTX has been the subject of a number of recent research reports. TD Cowen initiated coverage on shares of TG Therapeutics in a research note on Tuesday, October 29th. They issued a “buy” rating and a $50.00 price target for the company. StockNews.com downgraded shares of TG Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday, January 31st. HC Wainwright restated a “buy” rating and issued a $55.00 price target on shares of TG Therapeutics in a research note on Wednesday, January 15th. JPMorgan Chase & Co. upped their price objective on TG Therapeutics from $30.00 to $43.00 and gave the stock an “overweight” rating in a research report on Monday, November 25th. Finally, The Goldman Sachs Group increased their price objective on TG Therapeutics from $20.00 to $22.00 and gave the company a “neutral” rating in a report on Tuesday, November 5th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat.com, TG Therapeutics has an average rating of “Moderate Buy” and an average target price of $40.67.

Insider Activity at TG Therapeutics

In other TG Therapeutics news, CFO Sean A. Power sold 11,337 shares of the business’s stock in a transaction that occurred on Friday, January 3rd. The stock was sold at an average price of $30.29, for a total value of $343,397.73. Following the completion of the sale, the chief financial officer now owns 670,632 shares in the company, valued at approximately $20,313,443.28. The trade was a 1.66 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 10.50% of the company’s stock.

TG Therapeutics Stock Performance

Shares of TGTX stock opened at $30.71 on Friday. The stock’s 50-day moving average is $31.15 and its two-hundred day moving average is $27.36. The company has a debt-to-equity ratio of 1.27, a quick ratio of 3.91 and a current ratio of 4.59. TG Therapeutics, Inc. has a 1 year low of $12.84 and a 1 year high of $36.84. The firm has a market cap of $4.78 billion, a price-to-earnings ratio of -307.07 and a beta of 2.26.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.